Advertisement
Advertisement
Liquidia Corporation (LQDA)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 4.0300 |
| Open | 4.0400 |
| Bid | 3.9600 x 2200 |
| Ask | 4.2000 x 1400 |
| Day's Range | 3.9300 - 4.1700 |
| 52 Week Range | 2.2500 - 7.7800 |
| Volume | |
| Avg. Volume | 835,084 |
| Market Cap | 261.882M |
| Beta (5Y Monthly) | 0.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8000 |
| Earnings Date | Nov 04, 2021 - Nov 08, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.40 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for LQDA
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Liquidia CorporationDaily – Vickers Top Buyers & Sellers for 04/20/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast monthArgus Research
- Motley Fool
Why Liquidia Stock Rose as Much as 22% Higher Today
What happened Liquidia Technologies (NASDAQ: LQDA) stock went on quite a ride during Thursday's trading session. On the back of a new analyst take on the company, its shares climbed almost 22% higher in early action before settling down to a gain of slightly over 10% on the day.
- Zacks
United Therapeutics (UTHR) Gains on Tyvaso DPI Approval
The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.
- American City Business Journals
United Therapeutics gets long-awaited FDA approval as competitor Liquidia takes stock hit
United Therapeutics saw its stock jump after receiving approval from the FDA to launch a new treatment for pulmonary arterial hypertension. Liquidia is pursuing a similar drug.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
